The Experts below are selected from a list of 321 Experts worldwide ranked by ideXlab platform

Timothy J Craig - One of the best experts on this subject based on the ideXlab platform.

  • the effect of rhinitis on sleep quality of life Daytime Somnolence and fatigue
    2016
    Co-Authors: Geetika Sabharwal, Timothy J Craig
    Abstract:

    Allergic rhinitis affects 25 % of the world’s population. Nasal congestion is the most common and bothersome symptom of allergic rhinitis. Sleep impairment associated with the disease impacts the quality of life of patients with allergic rhinitis in a significant way. Intranasal steroids stand as effective treatment that significantly decreases nasal congestion which helps significantly with sleep and helps in decreasing the Daytime Somnolence and increases quality of life.

  • the role of pseudoephedrine on Daytime Somnolence in patients suffering from perennial allergic rhinitis par
    Annals of Allergy Asthma & Immunology, 2011
    Co-Authors: Amir Sherkat, Erik Lehman, Niti Sardana, Sahar Safaee, Timothy J Craig
    Abstract:

    Background Allergic rhinitis is one of several inflammatory diseases affecting the nasal mucosa. Cellular inflammation of nasal mucosa is a hallmark of this disease and is characterized by the accumulation of eosinophils and the release of various chemical messengers such as chemokines, cytokines, and histamine. This inflammation of the nose leads to nasal congestion and a reduction in sleep quality, resulting in Daytime Somnolence. Objective Drugs that significantly reduce the symptoms of nasal congestion also may help in alleviating sleep-related symptoms of allergic rhinitis. Pseudoephedrine is a sympathomimetic amine that is indicated for treatment of nasal congestion associated with allergic rhinitis. Despite relieving nasal congestion, we speculated that, because of pseudoephedrine's well-known stimulant profile, sleep would not be improved. Method Fourteen subjects who met the inclusion criteria were enrolled into a double-blind, placebo-controlled, randomized study to either pseudoephedrine or placebo once per day in the morning, using the traditional crossover design. Skin testing test was performed to ensure a positive response to a relevant perennial allergen and a negative response to a seasonal allergen. Several questionnaires were used to evaluate the patients' sleep-related symptoms, allergic rhinitis symptoms, and quality of life. Results Our results showed that pseudoephedrine did not have a positive or negative effect on quality of sleep, Daytime sleepiness, or Daytime fatigue as compared with placebo. Pseudoephedrine did show a statistical significance in improving stuffy nose ( P = .0172). With respect to quality of life, pseudoephedrine led to a statistically significant decrease in intimate relationships and sexual activity as compared with the placebo group ( P = .0310). Conclusion Our research suggests that sleep quality is not significantly affected by pseudoephedrine. As expected, congestion is reduced, but side effects such as a decline of intimate relationships and sexual activity may interfere with quality of life.

  • the role of montelukast on perennial allergic rhinitis and associated sleep disturbances and Daytime Somnolence
    Allergy and Asthma Proceedings, 2008
    Co-Authors: Carah B Santos, Christopher Hanks, Jeffrey Mccann, E L Pratt, Erik Lehman, Timothy J Craig
    Abstract:

    : Perennial allergic rhinitis (PAR) often causes sleep disturbances and associated Daytime Somnolence, thus resulting in a poor quality of life. Various clinical interventions in patients suffering from the disorder seek to improve symptoms and quality of life. Additional studies are needed to establish whether the alleviation of PAR symptoms, particularly the reduction of congestion, will improve sleep quality and reduce Daytime Somnolence. This study seeks to determine whether treatment with montelukast is more effective than placebo in reducing nasal congestion and sleep disturbances, resulting in reduced Daytime Somnolence and fatigue in patients with PAR. Thirty-one subjects were enrolled in a double-blinded, placebo-controlled study using Balaam's design. Patients were treated with montelukast or placebo. Collected subjective data included a daily diary recording nasal symptoms, sleep issues, and Daytime fatigue, the Functional Outcomes of Sleep Questionnaire, the Epworth Sleepiness Scale, Juniper's Rhinoconjunctivitis Quality of Life Questionnaire, the Rhinitis Severity Scale, the Calgary Sleep Apnea Quality of Life Index, and Trail Making tests. Subjects treated with montelukast, compared with placebo, showed a statistically significant improvement in Daytime Somnolence (p = 0.0089) and Daytime fatigue (p = 0.0087), with both factors improving with montelukast and worsening with placebo. In a small cohort of subjects, montelukast, when compared with placebo, improved the symptoms of PAR and reduced the fatigue and Daytime Somnolence associated with the disorder.

  • the importance of rhinitis on sleep Daytime Somnolence productivity and fatigue
    Current Opinion in Pulmonary Medicine, 2007
    Co-Authors: Lesley Woods, Timothy J Craig
    Abstract:

    Purpose of reviewThe goal of treatment of allergic rhinitis should include improvement of Daytime and nighttime symptoms, sleep, and quality of life. Congestion from allergic rhinitis is associated with decreased learning and productivity at work and school and a reduced quality of life. The release

  • allergic rhinitis and its effect on sleep fatigue and Daytime Somnolence
    Annals of Allergy Asthma & Immunology, 2006
    Co-Authors: Carah B Santos, Jeffery Mccann, E L Pratt, Chris Hanks, Timothy J Craig
    Abstract:

    Objective To examine the adverse effects of sleep impairment on the quality of life of patients with the disorder and how these effects can be treated with therapies targeted at the underlying problems that influence sleep. Data Sources Medline and Ovid search for sleep and rhinitis. Study Selection All literature on this topic were reviewed, and, if significant, were incorporated into this review. Results Intranasal corticosteroids used as treatment for allergic rhinitis have been shown to reduce the nasal congestion characteristic of the disorder. Data on sleep-related end points from clinical trials on intranasal corticosteroids also reveal that the treatment's effectiveness in alleviating nasal congestion leads to better sleep, reduced Daytime Somnolence, and improved quality of life. Conclusion Further research, specifically using sleep measurements as primary end points, is needed to definitively show that intranasal corticosteroids reduce nasal congestion, thereby improving sleep and, consequently, quality of life in patients with allergic rhinitis. These future trials will serve to identify the most effective therapies that target the adverse effects of sleep impairment in this disorder.

Erik Lehman - One of the best experts on this subject based on the ideXlab platform.

  • the role of pseudoephedrine on Daytime Somnolence in patients suffering from perennial allergic rhinitis par
    Annals of Allergy Asthma & Immunology, 2011
    Co-Authors: Amir Sherkat, Erik Lehman, Niti Sardana, Sahar Safaee, Timothy J Craig
    Abstract:

    Background Allergic rhinitis is one of several inflammatory diseases affecting the nasal mucosa. Cellular inflammation of nasal mucosa is a hallmark of this disease and is characterized by the accumulation of eosinophils and the release of various chemical messengers such as chemokines, cytokines, and histamine. This inflammation of the nose leads to nasal congestion and a reduction in sleep quality, resulting in Daytime Somnolence. Objective Drugs that significantly reduce the symptoms of nasal congestion also may help in alleviating sleep-related symptoms of allergic rhinitis. Pseudoephedrine is a sympathomimetic amine that is indicated for treatment of nasal congestion associated with allergic rhinitis. Despite relieving nasal congestion, we speculated that, because of pseudoephedrine's well-known stimulant profile, sleep would not be improved. Method Fourteen subjects who met the inclusion criteria were enrolled into a double-blind, placebo-controlled, randomized study to either pseudoephedrine or placebo once per day in the morning, using the traditional crossover design. Skin testing test was performed to ensure a positive response to a relevant perennial allergen and a negative response to a seasonal allergen. Several questionnaires were used to evaluate the patients' sleep-related symptoms, allergic rhinitis symptoms, and quality of life. Results Our results showed that pseudoephedrine did not have a positive or negative effect on quality of sleep, Daytime sleepiness, or Daytime fatigue as compared with placebo. Pseudoephedrine did show a statistical significance in improving stuffy nose ( P = .0172). With respect to quality of life, pseudoephedrine led to a statistically significant decrease in intimate relationships and sexual activity as compared with the placebo group ( P = .0310). Conclusion Our research suggests that sleep quality is not significantly affected by pseudoephedrine. As expected, congestion is reduced, but side effects such as a decline of intimate relationships and sexual activity may interfere with quality of life.

  • the role of montelukast on perennial allergic rhinitis and associated sleep disturbances and Daytime Somnolence
    Allergy and Asthma Proceedings, 2008
    Co-Authors: Carah B Santos, Christopher Hanks, Jeffrey Mccann, E L Pratt, Erik Lehman, Timothy J Craig
    Abstract:

    : Perennial allergic rhinitis (PAR) often causes sleep disturbances and associated Daytime Somnolence, thus resulting in a poor quality of life. Various clinical interventions in patients suffering from the disorder seek to improve symptoms and quality of life. Additional studies are needed to establish whether the alleviation of PAR symptoms, particularly the reduction of congestion, will improve sleep quality and reduce Daytime Somnolence. This study seeks to determine whether treatment with montelukast is more effective than placebo in reducing nasal congestion and sleep disturbances, resulting in reduced Daytime Somnolence and fatigue in patients with PAR. Thirty-one subjects were enrolled in a double-blinded, placebo-controlled study using Balaam's design. Patients were treated with montelukast or placebo. Collected subjective data included a daily diary recording nasal symptoms, sleep issues, and Daytime fatigue, the Functional Outcomes of Sleep Questionnaire, the Epworth Sleepiness Scale, Juniper's Rhinoconjunctivitis Quality of Life Questionnaire, the Rhinitis Severity Scale, the Calgary Sleep Apnea Quality of Life Index, and Trail Making tests. Subjects treated with montelukast, compared with placebo, showed a statistically significant improvement in Daytime Somnolence (p = 0.0089) and Daytime fatigue (p = 0.0087), with both factors improving with montelukast and worsening with placebo. In a small cohort of subjects, montelukast, when compared with placebo, improved the symptoms of PAR and reduced the fatigue and Daytime Somnolence associated with the disorder.

  • the effect of intranasal steroid budesonide on sleep disturbance and Daytime Somnolence in patients with perennial allergic rhinitis
    The Journal of Allergy and Clinical Immunology, 2004
    Co-Authors: Timothy J Craig, F Gurevich, Casey Glass, W Wei, Erik Lehman
    Abstract:

    Abstract Rationale The objective of this study was to determine whether intranasal corticosteroid budesonide reduced complaints of nasal congestion, poor sleep, Daytime fatigue, and Somnolence in patients with perennial allergic rhinitis (PAR). Methods Following IRB approval, twenty-six subjects were enrolled in a double-blind, placebo-controlled, crossover study using Balaam's design. Patients were treated with intranasal steroid spray budesonide or placebo. Epworth Sleepiness Scale, daily diary, and questionnaires were used as tools for subjective data analysis, which focused on nasal symptoms, sleep quality, Daytime Somnolence, and fatigue. The results were summarized and compared by PROC MIXED in SAS. Results The daily diary data showed significant improvement in nasal congestion (p=0.04) and Daytime sleepiness (p=0.01), and marginally significant reduction in Daytime fatigue (p=0.08) in the budesonide group compared to the placebo group. The sleep measures demonstrated statistically significant improvement in total sleep measures score (p=0.04), "sleep compared with absolute" (p=0.01), and "refreshing and restorative" sleep (p=0.04) in the active group. Conclusions Nasal corticosteroid budesonide is effective in reducing nasal congestion, Daytime Somnolence, and Daytime fatigue, and improving sleep quality and the PAR patients' quality of life.

  • efficacy of the topical nasal steroid budesonide on improving sleep and Daytime Somnolence in patients with perennial allergic rhinitis
    Allergy, 2003
    Co-Authors: Kathleen Hughes, F Gurevich, Casey Glass, L H Fisher, Michael Ripchinski, T E Weaver, Erik Lehman, Timothy J Craig
    Abstract:

    Background:  Improving quality of life is considered to be a major endpoint and motivation for clinical intervention in patients with perennial allergic rhinitis (PAR). In addition to classical symptoms of congestion, pruritus, and rhinorrhea, patients will often complain of not being able to sleep well at night and of feeling fatigued during the day. Like sleep apnea, PAR has also been shown to cause sleep disturbance and consequently worsen Daytime fatigue and Somnolence. Hypothesis: It is proposed that by decreasing nasal obstruction due to allergic rhinitis by treating with the topical steroid budesonide, symptoms of Daytime fatigue and Somnolence can be improved. Methods: Twenty-two subjects were enrolled in a double-blind, placebo-controlled, crossover study using Baalam's design. Patients were treated with either budesonide 128 μg/day or placebo. Subjective data include the Epworth Sleepiness Scale, Functional Outcomes of Sleep Questionnaire, Rhino-conjunctivitis Quality of Life Questionnaire, and a daily diary recording nasal symptoms, sleep problems, and Daytime fatigue. Results: The results illustrated that the topical nasal corticosteroid significantly improved Daytime fatigue (P = 0.03), Somnolence (P = 0.02), and quality of sleep (P = 0.05) compared to placebo in patients suffering from PAR. Summary: Budesonide is able to improve congestion, sleep, and Daytime Somnolence.

  • the effect of topical nasal fluticasone on objective sleep testing and the symptoms of rhinitis sleep and Daytime Somnolence in perennial allergic rhinitis
    Allergy and Asthma Proceedings, 2003
    Co-Authors: Timothy J Craig, Sujani Kakumanu, Cathy Mende, Kathleen Hughes, Erik Lehman, Vernon M. Chinchilli
    Abstract:

    : Recent data suggested that Daytime Somnolence in patients with allergic rhinitis was secondary to disrupted sleep caused by nasal congestion. Medications, which decreased congestion, would be expected to improve sleep and Daytime Somnolence. Previously, we showed that nasal steroids improved all three symptoms. Presently, we have not performed objective sleep testing to determine if there is a correlation between subjective improvement of congestion, sleep, and Daytime Somnolence. The objective of this 8-week, double-blind, placebo-controlled study was to determine if topical nasal fluticasone is effective at decreasing subjective congestion and Daytime Somnolence and improving sleep and if this improvement correlated with a change in overnight sleep testing (polysomnography). We recruited 32 subjects with perennial allergic rhinitis and randomized them in a double-blinded, cross-over fashion, to receive placebo or fluticasone (50 micrograms a spray), 2 sprays each side everyday, using Balaam's design. Questionnaires, quality of life instruments, daily diary, Epworth Sleepiness Scale, and an overnight sleep test with polysomnograms were used as tools. The last 2 weeks of each 4-week treatment period were summarized, scored, and compared by PROC MIXED in SAS. Correlations between arousals on sleep tests and subjective tests were performed. Fluticasone improved subjective sleep when compared with placebo (p = 0.04); however, there was no difference in the apnea/hypopnea index in those that were treated. Daytime sleepiness and fatigue were decreased by > 10% in the treated group; however, this was not statistically significant. However, fluticasone used at approved doses improves subjective sleep in patients with perennial allergic rhinitis without a change in the apnea/hypopnea index.

David Cunnington - One of the best experts on this subject based on the ideXlab platform.

  • excessive Daytime Somnolence in spinocerebellar ataxia type 1
    Journal of the Neurological Sciences, 2010
    Co-Authors: Dien Dang, David Cunnington
    Abstract:

    Autosomal dominant spinocerebellar ataxias (SCAs) are progressive neurodegenerative disorders which result in dysfunction of the neuronal systems of the spinal cord, brainstem, and cerebellum. The manifestations of Daytime Somnolence and abnormal sleep behavior have been described in SCA type 3 (SCA3) and SCA type 6 (SCA6), but as yet have not been described in SCA type 1 (SCA1). We report two cases of sleep disturbance, fatigue and excessive Daytime Somnolence in individuals with SCA1 and their progress through several therapies. These case studies are unique as they describe excessive Daytime Somnolence and sleep abnormalities in SCA1.

L H Fisher - One of the best experts on this subject based on the ideXlab platform.

  • how do topical nasal corticosteroids improve sleep and Daytime Somnolence in allergic rhinitis
    The Journal of Allergy and Clinical Immunology, 2005
    Co-Authors: Timothy J Craig, Christopher Hanks, L H Fisher
    Abstract:

    Therapy for rhinitis improves sleep quality and symptoms of Daytime sleepiness. This improvement with therapy may be secondary to anti-inflammatory effects, leading to a reduction of inflammatory mediators, or to a mechanical reduction of congestion directly leading to improvement in sleep disturbance. We combined our data from 3 placebo-controlled studies of intranasal corticosteroids in patients with perennial rhinitis to determine whether a correlation between the reduction of congestion and improved sleep and Daytime Somnolence existed. The pooled data of budesonide, flunisolide, and fluticasone demonstrated significantly decreased nasal congestion, sleep problems, and sleepiness in treated patients. The data demonstrated a correlation between a reduction in nasal congestion and an improvement of sleep ( P P = .01). Thus, topical intranasal corticosteroids should be used to decrease nasal congestion and to improve sleep and Daytime Somnolence in patients manifesting these symptoms.

  • the effect of intranasal steroid budesonide on the congestion related sleep disturbance and Daytime Somnolence in patients with perennial allergic rhinitis
    Allergy and Asthma Proceedings, 2005
    Co-Authors: F Gurevich, Casey Glass, Jeffery Mccann, L H Fisher, Salman Chegini, Cathy Mende, Michael J. Davies, Timothy J Craig
    Abstract:

    Abstract Patients with perennial allergic rhinitis (PAR) often present with nasal congestion, poor sleep, Daytime fatigue, and Daytime Somnolence. Pharmacologic therapy that reduces nasal congestion should improve the PAR patients' sleep quality and reduce Daytime Somnolence and fatigue. Our hypothesis is that intranasal steroid budesonide (BUD), an effective topical anti-inflammatory agent, will reduce nasal congestion and improve the patients' quality of life. The objective of this study was to determine whether topical steroid BUD improves sleep, Daytime Somnolence, and fatigue in patients with PAR. Twenty-six subjects were enrolled in a double-blind, placebo-controlled, crossover study using Balaam's design. Patients were treated with intranasal steroid spray BUD or placebo. The Epworth Sleepiness Scale, daily diary, and questionnaires were used as tools for subjective data analysis, which focused on nasal symptoms, sleep quality, Daytime Somnolence, and fatigue. The results were summarized and compared by PROC MIXED in SAS. The daily diary data showed significant improvement in self-reported nasal congestion (p = 0.04) and Daytime sleepiness (p = 0.01) and a trend in reduction of Daytime fatigue (p = 0.08) in the BUD group compared with the placebo group. The sleep measures showed statistically significant improvement in total sleep measures score (p = 0.04), "sleep compared with absolute" (p = 0.01), and "refreshing and restorative" sleep (p = 0.04) in the active group. Nasal corticosteroid BUD is effective in reducing nasal congestion, Daytime Somnolence, and Daytime fatigue, and improving sleep quality in PAR.

  • efficacy of the topical nasal steroid budesonide on improving sleep and Daytime Somnolence in patients with perennial allergic rhinitis
    Allergy, 2003
    Co-Authors: Kathleen Hughes, F Gurevich, Casey Glass, L H Fisher, Michael Ripchinski, T E Weaver, Erik Lehman, Timothy J Craig
    Abstract:

    Background:  Improving quality of life is considered to be a major endpoint and motivation for clinical intervention in patients with perennial allergic rhinitis (PAR). In addition to classical symptoms of congestion, pruritus, and rhinorrhea, patients will often complain of not being able to sleep well at night and of feeling fatigued during the day. Like sleep apnea, PAR has also been shown to cause sleep disturbance and consequently worsen Daytime fatigue and Somnolence. Hypothesis: It is proposed that by decreasing nasal obstruction due to allergic rhinitis by treating with the topical steroid budesonide, symptoms of Daytime fatigue and Somnolence can be improved. Methods: Twenty-two subjects were enrolled in a double-blind, placebo-controlled, crossover study using Baalam's design. Patients were treated with either budesonide 128 μg/day or placebo. Subjective data include the Epworth Sleepiness Scale, Functional Outcomes of Sleep Questionnaire, Rhino-conjunctivitis Quality of Life Questionnaire, and a daily diary recording nasal symptoms, sleep problems, and Daytime fatigue. Results: The results illustrated that the topical nasal corticosteroid significantly improved Daytime fatigue (P = 0.03), Somnolence (P = 0.02), and quality of sleep (P = 0.05) compared to placebo in patients suffering from PAR. Summary: Budesonide is able to improve congestion, sleep, and Daytime Somnolence.

Aleksandra Zgierska - One of the best experts on this subject based on the ideXlab platform.

  • snoring and excessive Daytime Somnolence and risk of cardiovascular diseases
    Polskie Archiwum Medycyny Wewnetrznej-polish Archives of Internal Medicine, 2001
    Co-Authors: Michal Bednarek, Maria Polakowska, Aleksandra Zgierska, Pawel Kurjata, Witold Kupśc, Robert Plywaczewski, Jan Zielinski
    Abstract:

    Abstract Snoring and excessive Daytime Somnolence (EDS) are very common in middle-age adults. The goal of the investigation was to assess links between those symptoms and risk for cardiovascular diseases (CVD). The population studied included 1186 inhabitants of Warsaw (mean age 52 years), participants of the international multicentre study of cardiovascular disease MONICA II, who completed the sleep disordered breathing (SDB) questionnaire. Snoring was reported by 78% of males (48% habitual and 30% occasional) and 59% of females (27% habitual and 32% occasional). Every fourth (26.8%) subject declared observed apnoeas, in 9.2% apnoeas were observed every night. EDS was declared by 28.7% of studied sample. The results of the questionnaire were compared to the results of MONICA study. Snorers had significantly higher systolic and diastolic blood pressure (133.2 +/- 23/84.6 +/- 13 mm Hg) compared to non-snorers (126.4 +/- 22/80.4 +/- +/- 12 mm Hg) (p or = 200 mg%) and triglycerides (> or = 200 mg%) concentration, and also obesity (BMI > or = 30 kg/m2) were more prevalent in snorers. Subjects reporting apnoeas more often had coronary artery disease (p < 0.001) or history of stroke (p = 0.002) compared to non-apnoeics. There was no relationship between EDS and risk of cardiovascular disorders, and also between diabetes and SDB. In conclusion, snoring was strongly associated with hyperlipidaemia, obesity or hypertension, well known risk factors for development of cardiovascular disorders. Reported apnoeas were related to risk of coronary artery disease.

  • snoring and excessive Daytime Somnolence among polish middle aged adults
    European Respiratory Journal, 1999
    Co-Authors: Jan Zielinski, Aleksandra Zgierska, Pawel Kurjata, M Polakowska, Laurel Finn, W Kupśc, Terry Young
    Abstract:

    There is considerable interest in the association of snoring and health consequences that have been linked to more severe sleep-disordered breathing, including obstructive sleep apnoea syndrome. The goal of this investigation was to assess the independent association of heavy, habitual snoring and Daytime sleepiness. For this, a cross-sectional, population based study of snoring, sleepiness and other factors was conducted using the Warsaw sample of the Multinational Monitoring of Trends and Determinants of Cardiovascular Diseases (MONICA) study, a population-based multicentre study of cardiovascular disease. The well-defined MONICA sample of middle-aged males and females also allowed estimation of age- and sex-specific prevalences of habitual snoring in Polish adults. Data on self-reported snoring frequency and loudness, and Daytime sleepiness using the Epworth Sleepiness Scale (ESS) and other questions, were collected with a postal questionnaire. Seventy-nine per cent of the MONICA sample completed the questionnaire, yielding a total of 1,186 participants. Of the total sample, 27% of the females and 48% of the males reported habitual snoring ("often" or "always"). There was an independent association of habitual snoring and excessive Daytime sleepiness (EDS), sleepiness that interfered with work and with increasing ESS scores. Habitual snorers were 5.8 and 3.1 times more likely to report EDS in active and passive situations, respectively, compared to nonsnorers (all p

  • snoring and excessive Daytime Somnolence among polish middle aged adults
    European Respiratory Journal, 1999
    Co-Authors: Jan Zielinski, Aleksandra Zgierska, Pawel Kurjata, Witold Kupśc, M Polakowska, Laurel Finn, Terry Young
    Abstract:

    There is considerable interest in the association of snoring and health consequences that have been linked to more severe sleep-disordered breathing, including obstructive sleep apnoea syndrome. The goal of this investigation was to assess the independent association of heavy, habitual snoring and Daytime sleepiness. For this, a cross-sectional, population based study of snoring, sleepiness and other factors was conducted using the Warsaw sample of the Multinational Monitoring of Trends and Determinants of Cardiovascular Diseases (MONICA) study, a population-based multicentre study of cardiovascular disease. The well-defined MONICA sample of middle-aged males and females also allowed estimation of age- and sex-specific prevalences of habitual snoring in Polish adults. Data on self-reported snoring frequency and loudness, and Daytime sleepiness using the Epworth Sleepiness Scale (ESS) and other questions, were collected with a postal questionnaire. Seventy-nine per cent of the MONICA sample completed the questionnaire, yielding a total of 1,186 participants. Of the total sample, 27% of the females and 48% of the males reported habitual snoring ("often" or "always"). There was an independent association of habitual snoring and excessive Daytime sleepiness (EDS), sleepiness that interfered with work and with increasing ESS scores. Habitual snorers were 5.8 and 3.1 times more likely to report EDS in active and passive situations, respectively, compared to nonsnorers (all p<0.01). It is concluded that habitual snorers, most of whom are probably unlikely to have frank sleep apnoea syndrome, are at substantial risk for Daytime sleepiness. These findings add support to the hypothesis that simple snoring is not benign and underscores the need for further research on health outcomes associated with this prevalent condition.

  • Excessive Daytime Somnolence in the adult population of Warsaw
    Polskie Archiwum Medycyny Wewnetrznej-polish Archives of Internal Medicine, 1998
    Co-Authors: J. Zieliński, Maria Polakowska, Kurjata P, Kupść W, Aleksandra Zgierska
    Abstract:

    We studied prevalence of excessive Daytime Somnolence (EDS) in a representative cohort of people living in Warsaw, aged 38-67y. Forty eight items questionnaire concerning sleep habits and symptoms including Epworth Sleepiness Scale assessing EDS was mailed twice to 1503 subjects. The response rate was 79%. The average sleep time on working days was 7.1 +/- 1.1h and 8.1 +/- 1.3h on week-ends. Moderate DS was found in 21% and severe DS in 7.5% of the studied group. 0.4% of studied subjects admitted falling asleep while driving a car. These figures are comparable to that reported in recent literature. There was no relation between EDS and short hours of sleep. Severe DS was twice as frequent among men than among women (p < 0.001). There was no clear-cut relations between age and EDS.